Premium
Treatment of resistant pemphigus vulgaris with an anti‐CD20 monoclonal antibody (Rituximab)
Author(s) -
Cooper H. L.,
Healy E.,
Theaker J. M.,
Friedmann P. S.
Publication year - 2003
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1046/j.1365-2230.2003.01283.x
Subject(s) - pemphigus vulgaris , rituximab , medicine , monoclonal antibody , cd20 , monoclonal , immunology , pemphigus , dermatology , antibody
Summary We describe a 54‐year‐old man with resistant pemphigus vulgaris. Standard therapies had afforded inadequate control and have been associated with considerable side‐effects. The anti‐CD20 monoclonal antibody, Rituximab (MabThera, Roche), was trialled with significant benefit. We discuss its potential mechanism of action.